Art. -Nr.: HY-13680

Meisoindigo

Name: Meisoindigo
Brand: MedChemExpress
SKU: HY-13680
Price: 32.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: Dian III; N-Methylisoindigotin; Natura-α)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.91%
CAS. Nr.: 97207-47-1
Formel: C₁₇H₁₂N₂O₂
Molecular Weight:276.29

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Meisoindigo Chemical Structure

CAS. Nr.: 97207-47-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (8)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	6.57 μM Compound: Mei	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
A549	IC₅₀	57.3 μM Compound: 6a, MIO, Meisoindigo	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 25151579]
COLO 205	IC₅₀	7.55 μM Compound: Mei	Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HCT-116	IC₅₀	15.4 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19783149]
HCT-116	IC₅₀	27 μM Compound: 6a, MIO, Meisoindigo	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 25151579]
HCT-116	IC₅₀	5.36 μM Compound: Mei	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HeLa	IC₅₀	15.7 μM Compound: 6a, MIO, Meisoindigo	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 25151579]
HL-60	IC₅₀	12.2 μM Compound: 2	Antiproliferative activity against human HL60 cells after 5 days by MTT assay Antiproliferative activity against human HL60 cells after 5 days by MTT assay	[PMID: 19783149]
Huh-7	IC₅₀	18.3 μM Compound: 2	Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay	[PMID: 19783149]
IMR-90	IC₅₀	7.7 μM Compound: 2	Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay	[PMID: 19783149]
K562	IC₅₀	23.3 μM Compound: 6a, MIO, Meisoindigo	Cytotoxicity against human K562 cells after 48 hrs by SRB assay Cytotoxicity against human K562 cells after 48 hrs by SRB assay	[PMID: 25151579]
K562	IC₅₀	6.7 μM Compound: 2	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 19783149]
K562	IC₅₀	8.17 μM Compound: Mei	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
L1210	IC₅₀	167 μM Compound: 6a, MIO, Meisoindigo	Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay	[PMID: 25151579]
LoVo	IC₅₀	12.67 μM Compound: Mei	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
MGC-803	IC₅₀	128 μM Compound: 6a, MIO, Meisoindigo	Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay	[PMID: 25151579]
NCI-H358	IC₅₀	>20 μM Compound: Mei	Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
RKO	IC₅₀	11.63 μM Compound: Mei	Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW13	IC₅₀	12.89 μM Compound: Mei	Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW480	IC₅₀	2.8 μM Compound: Mei	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW-620	IC₅₀	9.14 μM Compound: Mei	Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]

In Vitro

Meisoindigo (Dian III; 5-20 μM; for 24?hours) inhibits growth of the AML cell lines^[1].
Meisoindigo (10?μM; for 24?hours) induces apoptosis of acute myeloid leukemia^[1].
Meisoindigo (5-10?μM; for 24?hours) causes cell-cycle arrest^[1].
Meisoindigo (5-10?μM; for 24?hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells^[1].
Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[1]

View Protocol

Cell Line:

HL-60, NB4, U937 leukemic cell lines
Concentration:

5, 10, 15, 20 μM
Incubation Time:

For 24 hours
Result:

Inhibited growth of the AML cell lines in a dose- and time-dependent manner.

Apoptosis Analysis^[1]

View Protocol

Cell Line:

HL-60 cells
Concentration:

10 μM
Incubation Time:

For 24 hours
Result:

Induced apoptosis of acute myeloid leukemia.

Cell Cycle Analysis^[1]

View Protocol

Cell Line:

HL-60 cells
Concentration:

5, 10 μM
Incubation Time:

For 24 hours
Result:

Caused cell-cycle arrest, with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase, in a dose-dependent manner.

Western Blot Analysis^[1]

View Protocol

Cell Line:

HL-60 cells
Concentration:

5, 10 μM
Incubation Time:

For 24 hours
Result:

Increased the cleaved caspase-3 and pro-apoptotic Bak, and decreased Bcl-2 and Bcl-xL levels in HL-60 cells.

In Vivo

Meisoindigo (Dian III; 50-150?mg/kg; IP; daily; for 14 days) has anti-leukemic activity in?vivo^[1].
Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cells^[1]
Dosage:

50, 100, 150 mg/kg
Administration:

IP; daily; for 14 days
Result:

Had anti-leukemic activity in vivo.

Chemical Information

CAS. Nr. 97207-47-1
Appearance Solid
Molecular Weight 276.29
Formel C₁₇H₁₂N₂O₂
Color Grayish brown to reddish brown
SMILES

O=C1N(C)C2=C(C=CC=C2)/C1=C3C(NC4=C\3C=CC=C4)=O
Synonyms

Dian III; N-Methylisoindigotin; Natura-α
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
- Plants
- Other Families Extract
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Cancer Res

Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. [Abstract]

2025 Nov 21:10.1158/0008-5472.CAN-24-3753. PMID: 41270153
bioRxiv

2024 October 25.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 51 mg/mL (184.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6194 mL

18.0969 mL

36.1939 mL

5 mM

0.7239 mL

3.6194 mL

7.2388 mL

10 mM

0.3619 mL

1.8097 mL

3.6194 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Cell Biology Signal Pathway Related Animals and Diseases

Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee CC, et al. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leuk Lymphoma. 2010 May;51(5):897-905. [Content Brief]

[2]. Yingze Ye, et al. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front Cell Neurosci. 2019 Dec 16;13:553. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6194 mL	18.0969 mL	36.1939 mL	90.4846 mL
	5 mM	0.7239 mL	3.6194 mL	7.2388 mL	18.0969 mL
	10 mM	0.3619 mL	1.8097 mL	3.6194 mL	9.0485 mL
	15 mM	0.2413 mL	1.2065 mL	2.4129 mL	6.0323 mL
	20 mM	0.1810 mL	0.9048 mL	1.8097 mL	4.5242 mL
	25 mM	0.1448 mL	0.7239 mL	1.4478 mL	3.6194 mL
	30 mM	0.1206 mL	0.6032 mL	1.2065 mL	3.0162 mL
	40 mM	0.0905 mL	0.4524 mL	0.9048 mL	2.2621 mL
	50 mM	0.0724 mL	0.3619 mL	0.7239 mL	1.8097 mL
	60 mM	0.0603 mL	0.3016 mL	0.6032 mL	1.5081 mL
	80 mM	0.0452 mL	0.2262 mL	0.4524 mL	1.1311 mL
	100 mM	0.0362 mL	0.1810 mL	0.3619 mL	0.9048 mL

Bioz

Meisoindigo

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Meisoindigo

Publications Citing Use of MedChemExpress (MCE) Meisoindigo